Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Online

May 15, 2017 12:00 PM - May 18, 2017 1:30 PM

Basics of the IND

Part 2

Session Chair(s)

Elliott  Berger, PhD, MS

Elliott Berger, PhD, MS

President

ETB Regualtory Consulting, United States

The IND in Detail - Items 1-6

  • IND Item 1: Form FDA 1571
  • IND Item 2: Table of Contents
  • IND Item 3: Introductory Statement
  • IND Item 4: General Investigation Plan
  • IND Item 5: Investigator’s Brochure
  • IND Item 6: Protocols
Special Topics for Clinical Research
  • Adequate and Well-controlled Trials
  • Adaptive Study Designs
  • Comparative Effectiveness Research (CER)
  • Patient Reported Outcomes
  • Surrogate Endpoints
  • The Animal Efficacy Rule
  • Qualification of Drug Development Tools
  • Foreign Clinical Trials
  • Changes to the Investigational Drug
  • Financial Disclosure by Clinical Investigators
Questions/Answers

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.